NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

NCCN has designated Optune as first line therapy. Seems to contradict you statement.
"NCCN - CATEGORY 1
Part of a National Comprehensive Cancer Network® (NCCN®)Category 1 Recommendation
for newly diagnosed GBM5
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers include alternating electric field therapy (Optune®) together with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as a Category 1 recommended treatment option for patients with newly diagnosed supratentorial GBM and good performance status. The NCCN-preferred adjuvant treatment regimen is radiation therapy with concurrent and adjuvant TMZ +/- Optune. There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1).5,‡"

Clinical trial findings for Optune: "No significant increase in serious AEs compared with TMZ alone" https://www.optune.com/hcp/newly-diagnosed-gbm/safety